Help America's Universities Keep Transforming the World


By Lita Nelsen

When I was a student at the Massachusetts Institute of Technology decades ago, Cambridge's Kendall Square was a grubby, run-down warehouse district. Today, it's known as the most innovative square mile on the planet.

The secret? The Bayh-Dole Act, a landmark piece of legislation passed in 1980 that allowed universities to keep the patents to any inventions they made. That meant that they could license these inventions to private companies, who would turn the new scientific knowledge into innovative products.

That one forward-looking law attracted hundreds of biotechnology companies to MIT's backyard, helping to breathe new life into Kendall Square and revitalize Massachusetts's economy. Cambridge, Mass., of course, wasn't the only university community to thrive because of Bayh-Dole. Cities and towns surrounding hundreds of universities have prospered as a result.

Nevertheless, Bayh-Dole has recently come under attack by lawmakers who want to use the law as a mechanism to cut drug prices. Their goal of lowering drug prices for patients is admirable -- but twisting the Bayh-Dole Act to use it as a price control tool would have disastrous consequences for America's research universities, as well as U.S. consumers and patients, who will suffer as a result of any reduced investment in life sciences.

In a recent letter in support of this idea, lawmakers urged administrators at the Department of Health and Human Services to use Bayh-Dole to "march-in" and take away drug companies' licenses to certain patents that stemmed from taxpayer-funded research. HHS could then relicense those drug patents to generic pharmaceutical companies that could create cheaper versions of the medicines.

That's certain to make biotech investors and companies less willing to invest in university research. Why would any firm -- small companies and startups especially -- assume the risk of developing a new drug when the government could seize its patent rights if federal officials don't like the price of the final product?

Lawmakers would do well to remember that Bayh-Dole fundamentally changed the research and development landscape in the United States for the better.

I should know. As the head of MIT's Technology Licensing Office for almost three decades, I helped license thousands of technologies to the innovative companies that sprung up around campus.

Before Bayh-Dole, the government retained patent rights to any academic discoveries supported by public money, and licensed just 5% of the nearly 30,000 patents it held. Consequently, while this pre-Bayh-Dole system worked to advance basic research, it failed to turn scientific advancement into usable, commercial products.

Bayh-Dole shifted that paradigm, providing a mechanism to translate academic research results into new technologies ranging from high-definition television and the page-rank algorithm that would become Google to FluMist® and CAR T-cell therapy. Companies exploiting Bayh-Dole inventions have contributed up to $1.9 trillion to the U.S. gross industrial output and up to $1 trillion to our GDP. They have supported nearly 6.5 million jobs and led to the creation of over 15,000 startups.

The bipartisan Bayh-Dole Act, as its authors clearly stated, was never meant to be a price-control mechanism. The law outlines four clearly defined instances where its march-in provisions can be exercised. Controlling prices is not one of them.

What today's lawmakers don't seem to grasp is that the unintended consequences of meddling with Bayh-Dole will outweigh any wished-for benefits.

Lita Nelsen retired from the Technology Licensing Office at the Massachusetts Institute of Technology after 30 years in the office. She was director of MIT TLO from 1992 to 2016. This op-ed originally ran in the Boston Herald.



More Resources


11/20/2024
What Donald Trump's Revenge Agenda Is Hiding
Look past the flashy and controversial Cabinet nominees to find that Project 2025 is already being implemented

more info


11/20/2024
Make Education Great Again!
Imagine these words as the first speech delivered by the incoming Secretary of Education.Today, I am here to deliver bitter medicine: American education has failed. Teachers and parents, administrato

more info


11/20/2024
Time-Honored Tradition of Blaming the Left for Dem Defeats
This argument is particularly unconvincing this time around. And it doesn't offer a realistic prescription for future success.

more info


11/20/2024
Dems Are Going To Get Younger and More Radical


more info


11/20/2024
The Blurred Line Between X and the Trump Administration
Forget the ridiculous

more info


11/20/2024
DOGE Is a Great Idea. Trump Should Make It Permanent
DOGE represents a harbinger of deregulation for an incoming Trump administration, especially with Dogecoin enthusiast Elon Musk and Vivek Ramaswamy at the helm.

more info


11/20/2024
The DOGE Plan To Reform Government
Following the Supreme Court's guidance, we'll reverse a decadeslong executive power grab.

more info


11/20/2024
Could Trump Actually Get Rid of the Department of Education?
Getting rid of the agency would cause a lot of harm and wouldn't really change school curriculum.

more info


11/20/2024
How Dems Are Losing Tomorrow's Elections Today
America is outgrowing the Democratic Party.

more info


11/20/2024
Can a Fractured Democratic Party Learn the Lessons of 2024?
After a bruising campaign season and a humiliating defeat at the polls, this week saw Dems' internal conflicts spilling out into public view. Party insiders are now engaged in tit-for-tat Twitter battles that do nothing to offer the party a roadmap back to political contender status. Instead, they confirm normies' worst caricatures of Democratic dysfunction.

more info


11/20/2024
Pennsylvania Voters to Sen. Casey: 'It's Over, Bob'
Columnist David Marcus talks to voters in Bucks County and finds Democrats and Republicans agree that Sen. Bob Casey's refusal to concede is a bad look.

more info


11/20/2024
NC Republicans' Shameless New Power Grab
North Carolina voters spoke loud and clear two weeks ago when they elected Democrats to some of the most prominent statewide offices.

more info


11/20/2024
Trump Can and Should Fire Jerome Powell
Legacy media have been obsessing over whether President-elect Donald Trump can remove Jerome Powell, chairman of the Federal Reserve (the Fed). Jerome Powell recently came out and stated he would serve out his term - which ends in 2026. Further, Chairman Powell claims any attempt by President Trump to remove him is not "permitted under the law." Unfortunately for Chairman Powell, President-elect Trump can remove him - and he should - to make the federal bureaucracy respond to democratic pressures once again.

more info


11/20/2024
SecDef Austin: Women in Military Make U.S. Stronger
Austin in an exclusive interview with NBC News called women in the military a strong asset. Trump's choice for Secretary of Defense has cast doubt on women in combat roles.

more info


11/20/2024
Drone, Missile Defense Top Priorities for Next Defense Secretary
Pete Hegseth faces critical challenges in addressing U.S. vulnerabilities to advanced missile and drone threats as global tensions rise.

more info



Custom Search

More Politics Articles:

Related Articles

Get Ready for an American Energy Comeback


Judging from the headlines, America's energy sector could collapse at any moment. Scattered amidst coronavirus coverage are reports of plummeting energy stocks and commodities traders paying people to take barrels of oil off their hands.

Trump Administration Should Reject Foreign Prescription Drug Price Controls


In responding to the coronavirus pandemic, President Trump has rightly focused on the tremendous innovative capacity of American businesses -- first by waiving regulations that impose unnecessary burdens, next by providing incentives to get tough jobs such as vaccine development done as quickly as possible.

Clearing the Air on the EPA's Coronavirus Response


The Environmental Protection Agency (EPA) agency recently issued a memo waiving certain compliance requirements for energy firms in light of the COVID-19 outbreak. A group of House Democrats falsely claimed the EPA's memo gives oil and gas companies an "open license to pollute." To address lawmakers' concerns, the EPA has tapped an internal watchdog to review the policy. But no matter how hard they look, the investigators won't find anything close to what Democrats have suggested.

If Trump is Not Reelected, America Will Be Hurting


Most every American has an opinion about the upcoming election. However, there are several realities we must face.

For Workers' Sake, Keep the Pressure on America's Trading Partners


In his marathon testimony before Congress earlier this summer, United States Trade Representative Robert Lighthizer detailed the trade-policy achievements of President Trump's first term. It's a list that should make the administration proud.

Superbugs will Kill Millions — Unless Congress Acts


We're in the midst of the worst health crisis of the 21st century -- and it's not COVID.

Why Do We Take to the Streets?


We Americans are quick to take our disagreements to the streets. In 2020, we have claimed many causes to do so. Millions came out to protest police violence and “resist” fascism. Others “rallied” against COVID-19 lockdowns and voter fraud. We may amass crowds to evoke sympathy or provoke debate. But demonstrations aggravate and intimidate, often drawing counter protesters if not ending in violence. And even when gatherings generate debate, we are tempted to settle them by who had the larger crowd size rather than the merits of the case.

Biden Administration Must Commit to a National Pandemic Preparedness Strategy


COVID-19 has killed more than 350,000 Americans. And with case counts and hospitalizations soaring, many more deaths are sadly in store.

The FDA Can Help Patients With Rare Diseases


When I was just 18 years old, I was diagnosed with hypoparathyroidism, a rare disease that causes seizures, extreme fatigue and other life-altering complications.

A Simple Fix for Biden to Help to Make Drugs More Affordable


Americans have problems affording many drugs at pharmacies and doctors' offices. About half of those who are sick have trouble paying for their medications, according to a recent poll from the Kaiser Family Foundation.

America is Ready For a Resurrection


The followers of Jesus believed in his resurrection because they saw him alive after he was dead. They had a powerful testimony of firsthand evidence seen with their own eyes.

Small Changes to 340B Can Make a Big Difference for Struggling Patients


The Covid-19 pandemic has made the issue of healthcare access more urgent than ever. Yet, at a time of deep divisions in Washington, chances for major reform are slim.

The Need for Reconciliation is a Sign of a Bad Bill


"Budget Reconciliation" may be the most popular phrase on Capitol Hill right now. This special legislative process allows certain bills to be passed in the Senate with a simple majority so long as they impact the budget.

America was Prepared to Fight Covid-19 Thanks to Intellectual Property Rights


When Covid-19 came ashore, glaring gaps in the government's pandemic preparedness became painfully obvious. Everything from inadequate stockpiles of personal protective equipment to confusing and uncoordinated guidance regarding closures hampered our early response.

Democrats Chose the Worst Time to Revive Medicare for All


Medicare for All just won't die. More than 100 House Democrats have signed onto new legislation that would outlaw all private insurance and put all Americans on a federally-run insurance plan within two years.